Antibody to treat bleeding caused by tpa when treating stroke

EmstoPA is focused on developing a novel tPA-neutralizing antidote designed to address the severe hemorrhage that can occur as a side effect of tPA, a life-saving drug often used in emergency situations. While tPA is effective in treating conditions like stroke, its potential to cause uncontrollable bleeding, particularly in the brain, limits its application. EmstoPA aims to fill this critical gap by providing an emergency treatment that can rapidly reverse the effects of tPA, thereby enhancing patient safety and expanding the drug's usability in clinical settings.

The company recognizes a significant unmet need for a solution that can quickly halt the adverse effects of tPA, which can lead to life-threatening situations. EmstoPA is positioned as the first product of its kind, offering a promising approach to mitigate the risks associated with tPA administration. By stopping bleeding and potentially saving lives, EmstoPA not only addresses a crucial medical challenge but also aims to reduce long-term disability for patients affected by tPA-related complications.

United Kingdom

EmstoPA is a first in class antibody-based reversal agent to treat bleeding caused by tissue plasminogen activator (tPA - Activase®, Alteplase®). tPA is a “clot buster” used to remove the blood clots that cause stroke, pulmonary embolism, and myocardial infarction. In the developed world, tPA is most frequently used to treat acute ischemic stroke where the rates of subsequent intracranial hemorrhage (ICH) are 5-7% .

EmstoPA belongs to a class of drugs called anti-fibrinolytics, and and the current market for antifibrinolytics is estimated to be $1,100m /year. Currently no specific tPA reversal agents are in
development.

EmstoPA

Company Details